Rockland Trust Co. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rockland Trust Co. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 402 shares of the biopharmaceutical company’s stock, valued at approximately $255,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Capital International Investors boosted its stake in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after acquiring an additional 155,369 shares during the period. Dodge & Cox boosted its position in Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock worth $1,653,543,000 after purchasing an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the period. Finally, Franklin Resources Inc. grew its stake in shares of Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock valued at $1,456,864,000 after purchasing an additional 149,124 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Citigroup dropped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating on the stock in a report on Monday, June 2nd. UBS Group decreased their price target on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating on the stock in a research report on Thursday, June 5th. The Goldman Sachs Group cut their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. Royal Bank of Canada lowered Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price objective for the company. in a research note on Friday, May 30th. Finally, Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research report on Friday, April 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $836.48.

Regeneron Pharmaceuticals Stock Up 1.4%

Shares of REGN stock opened at $529.24 on Friday. The company’s fifty day simple moving average is $563.19 and its two-hundred day simple moving average is $649.98. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock has a market cap of $57.14 billion, a P/E ratio of 13.83, a PEG ratio of 2.34 and a beta of 0.31. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the firm posted $9.55 earnings per share. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.